Premium
P4‐335: LONGITUDINAL ASSESSMENT OF THE NOVEL TAU TRACER [ 18 F]MK‐6240 FOR THE USE IN CLINICAL TRIALS
Author(s) -
Pascoal Tharick A.,
Chamoun Mira,
Benedet Andrea Lessa,
Kang Min Su,
Mathotaarachchi Sulantha,
Therriault Joseph,
Savard Melissa,
Iqbal Qureshi Muhammad Naveed,
Parson Marlee,
Tissot Cecile,
Lussier Firoza Zubeida,
Wachtelaer Eva,
Massarweh Gassan,
Soucy Jean-Paul,
Gauthier Serge,
Rosa-Neto Pedro
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4005
Subject(s) - posterior cingulate , voxel , sample size determination , nuclear medicine , standardized uptake value , clinical trial , anterior cingulate cortex , medicine , cortex (anatomy) , pathology , neuroscience , psychology , positron emission tomography , radiology , mathematics , statistics , cognition
selves (Fig.1C). Core nodes in each mask included regions targeted by the corresponding battery measures and/or regions involved in AD (Fig.2-3). Conclusions: Our framework improves test-retest reproducibility in FC plus stability, specificity, accuracy, and generalizability in estimating individual-level AD outcomes from individual-level FC measures. This improvement in reproducibility and accuracy in prediction of outcomes, at the individual-subject level, represents an important step in improving the clinical utility of FC biomarkers.